Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study.
螺內酯在IgA腎病治療中的有效性和安全性：一項回顧性自我對照研究。
Kidney Blood Press Res 2024-07-23
Comparative effectiveness and safety for the treatments despite optimized renin-angiotensin system blockade among IgA nephropathy patients at high-risk of disease progression: A network meta-analysis of randomized controlled trials.
IgA腎病高風險病患在最佳化腎素-血管緊張素系統阻斷治療下的治療比較效果和安全性：隨機對照試驗的網絡荟萃分析。
Eur J Intern Med 2023-08-11
The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy.
在具有組織學活性病變的免疫球蛋白A腎病患者中，以麥考酚酯酸鹽為基礎的方案對減少類固醇的效果：與接受傳統治療的對照組進行比較。
J Nephrol 2023-12-07
Efficacy of SGLT2 inhibitors in IgA nephropathy associated with alcoholic liver cirrhosis accompanied by nephrotic syndrome: a case report.
SGLT2抑制劑在伴有腎症候群的酒精性肝硬化IgA腎病的療效：一個病例報告。
Front Nephrol 2024-02-07
Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients: A Randomized Placebo-Controlled Clinical Trial.
螺內酮對腎移植接受者腎功能的影響：一項隨機安慰劑對照臨床試驗。
Clin J Am Soc Nephrol 2024-02-28
Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.
Sparsentan改善在IgA腎病小鼠模型中由IgA1-IgG免疫複合物誘導的腎小球過度細胞增生和炎症基因網絡。
Am J Physiol Renal Physiol 2024-03-21
[Anti-Proteinuric Effect of GLP1-RA as Add-On to SGLT2-i and ACE-i in a Diabetic Patient with IgA Nephropathy].
GLP1-RA作為SGLT2-i和ACE-i的附加用藥對一名IgA腎病糖尿病患者的抗蛋白尿效應。
G Ital Nefrol 2024-05-02
The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy.
高風險免疫球蛋白A腎病中減量口服甲基潑尼松的療效與安全性。
Kidney Int Rep 2024-07-31
一項針對減量甲基潑尼松（methylprednisolone）在免疫球蛋白 A 腎病（IgAN）患者中的研究顯示，這種治療能顯著降低重大腎臟事件的風險。接受治療的患者中，主要結果事件發生率明顯低於安慰劑組（7/121 vs 22/120），風險比為0.24，顯示出良好的保護效果。此外，治療還減少了蛋白尿，並使腎小球過濾率下降速度變慢。不過，隨著時間推移，這些好處會減少，且甲基潑尼松組的嚴重不良事件發生率較高，特別是感染。因此，雖然對高風險的 IgAN 患者有效，但也需注意增加的風險。
PubMedDOI